LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 6 of total 6

Search options

  1. Book ; Online ; Thesis: Analysis of high-throughput screening data for precision oncology and antibiotic combination modelling

    Kim, Vladislav [Verfasser] / Huber, Wolfgang [Akademischer Betreuer]

    2021  

    Author's details Vladislav Kim ; Betreuer: Wolfgang Huber
    Keywords Naturwissenschaften ; Science
    Subject code sg500
    Language English
    Publisher Universitätsbibliothek Heidelberg
    Publishing place Heidelberg
    Document type Book ; Online ; Thesis
    Database Digital theses on the web

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  2. Article ; Online: Comparing the value of mono- vs coculture for high-throughput compound screening in hematological malignancies.

    Herbst, Sophie A / Kim, Vladislav / Roider, Tobias / Schitter, Eva C / Bruch, Peter-Martin / Liebers, Nora / Kolb, Carolin / Knoll, Mareike / Lu, Junyan / Dreger, Peter / Müller-Tidow, Carsten / Zenz, Thorsten / Huber, Wolfgang / Dietrich, Sascha

    Blood advances

    2023  Volume 7, Issue 19, Page(s) 5925–5936

    Abstract: Large-scale compound screens are a powerful model system for understanding variability of treatment response and discovering druggable tumor vulnerabilities of hematological malignancies. However, as mostly performed in a monoculture of tumor cells, ... ...

    Abstract Large-scale compound screens are a powerful model system for understanding variability of treatment response and discovering druggable tumor vulnerabilities of hematological malignancies. However, as mostly performed in a monoculture of tumor cells, these assays disregard modulatory effects of the in vivo microenvironment. It is an open question whether and to what extent coculture with bone marrow stromal cells could improve the biological relevance of drug testing assays over monoculture. Here, we established a high-throughput platform to measure ex vivo sensitivity of 108 primary blood cancer samples to 50 drugs in monoculture and coculture with bone marrow stromal cells. Stromal coculture conferred resistance to 52% of compounds in chronic lymphocytic leukemia (CLL) and 36% of compounds in acute myeloid leukemia (AML), including chemotherapeutics, B-cell receptor inhibitors, proteasome inhibitors, and Bromodomain and extraterminal domain inhibitors. Only the JAK inhibitors ruxolitinib and tofacitinib exhibited increased efficacy in AML and CLL stromal coculture. We further confirmed the importance of JAK-STAT signaling for stroma-mediated resistance by showing that stromal cells induce phosphorylation of STAT3 in CLL cells. We genetically characterized the 108 cancer samples and found that drug-gene associations strongly correlated between monoculture and coculture. However, effect sizes were lower in coculture, with more drug-gene associations detected in monoculture than in coculture. Our results justify a 2-step strategy for drug perturbation testing, with large-scale screening performed in monoculture, followed by focused evaluation of potential stroma-mediated resistances in coculture.
    MeSH term(s) Humans ; Coculture Techniques ; Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy ; Leukemia, Lymphocytic, Chronic, B-Cell/pathology ; Drug Resistance, Neoplasm ; Leukemia, Myeloid, Acute ; Hematologic Neoplasms/drug therapy ; Tumor Microenvironment
    Language English
    Publishing date 2023-06-23
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2915908-8
    ISSN 2473-9537 ; 2473-9529
    ISSN (online) 2473-9537
    ISSN 2473-9529
    DOI 10.1182/bloodadvances.2022009652
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 7153: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article: RNA-Seq workflow: gene-level exploratory analysis and differential expression.

    Love, Michael I / Anders, Simon / Kim, Vladislav / Huber, Wolfgang

    F1000Research

    2015  Volume 4, Page(s) 1070

    Abstract: Here we walk through an end-to-end gene-level RNA-Seq differential expression workflow using Bioconductor packages. We will start from the FASTQ files, show how these were aligned to the reference genome, and prepare a count matrix which tallies the ... ...

    Abstract Here we walk through an end-to-end gene-level RNA-Seq differential expression workflow using Bioconductor packages. We will start from the FASTQ files, show how these were aligned to the reference genome, and prepare a count matrix which tallies the number of RNA-seq reads/fragments within each gene for each sample. We will perform exploratory data analysis (EDA) for quality assessment and to explore the relationship between samples, perform differential gene expression analysis, and visually explore the results.
    Language English
    Publishing date 2015
    Publishing country England
    Document type Journal Article
    ZDB-ID 2699932-8
    ISSN 2046-1402
    ISSN 2046-1402
    DOI 10.12688/f1000research.7035.1
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: An autologous culture model of nodal B-cell lymphoma identifies ex vivo determinants of response to bispecific antibodies.

    Roider, Tobias / Brinkmann, Berit J / Kim, Vladislav / Knoll, Mareike / Kolb, Carolin / Roessner, Philipp M / Bordas, Marie / Dreger, Peter / Müller-Tidow, Carsten / Huber, Wolfgang / Seiffert, Martina / Dietrich, Sascha

    Blood advances

    2021  Volume 5, Issue 23, Page(s) 5060–5071

    Abstract: Bispecific antibodies (BsAbs) can induce long-term responses in patients with refractory and relapsed B-cell lymphoma. Nevertheless, response rates across patients are heterogeneous, and the factors determining quality and duration of responses are ... ...

    Abstract Bispecific antibodies (BsAbs) can induce long-term responses in patients with refractory and relapsed B-cell lymphoma. Nevertheless, response rates across patients are heterogeneous, and the factors determining quality and duration of responses are poorly understood. To identify key determinants of response to BsAbs, we established a primary, autologous culture model allowing us to mimic treatment with CD3xCD19 and CD3xCD20 BsAbs within the lymph node microenvironment ex vivo. T cell-mediated killing of lymphoma cells and proliferation of T cells varied significantly among patients but highly correlated between BsAbs targeting CD20 or CD19. Ex vivo response to BsAbs was significantly associated with expansion of T cells and secretion of effector molecules (eg, granzyme B, perforin) but not with expression of T-cell exhaustion (eg, PD1, TIM3) or activation markers (eg, CD25, CD69) or formation of intercellular contacts. In addition, we identified a distinct phenotype of regulatory T cells that was linked to ex vivo response independently from T-cell frequency at baseline. High expression levels of Aiolos (IKZF1), ICOS, and CXCR5 were positively associated with ex vivo response, whereas strong expression of Helios (IKZF2) had an unfavorable impact on ex vivo response to BsAbs. We further showed that lenalidomide, nivolumab, and atezolizumab improved ex vivo response to BsAbs by potentiating T-cell effector functions. In summary, our ex vivo study identified a distinct regulatory T-cell phenotype as a potential contributor to treatment failure of BsAbs and suggests drug combinations of high clinical relevance that could improve the efficacy of BsAbs.
    MeSH term(s) Antibodies, Bispecific/pharmacology ; Antigens, CD19 ; Humans ; Lymphoma, B-Cell ; Tumor Microenvironment
    Chemical Substances Antibodies, Bispecific ; Antigens, CD19
    Language English
    Publishing date 2021-09-29
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2915908-8
    ISSN 2473-9537 ; 2473-9529
    ISSN (online) 2473-9537
    ISSN 2473-9529
    DOI 10.1182/bloodadvances.2021005400
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 7153: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Systematic analysis of drug combinations against Gram-positive bacteria.

    Cacace, Elisabetta / Kim, Vladislav / Varik, Vallo / Knopp, Michael / Tietgen, Manuela / Brauer-Nikonow, Amber / Inecik, Kemal / Mateus, André / Milanese, Alessio / Mårli, Marita Torrissen / Mitosch, Karin / Selkrig, Joel / Brochado, Ana Rita / Kuipers, Oscar P / Kjos, Morten / Zeller, Georg / Savitski, Mikhail M / Göttig, Stephan / Huber, Wolfgang /
    Typas, Athanasios

    Nature microbiology

    2023  Volume 8, Issue 11, Page(s) 2196–2212

    Abstract: Drug combinations can expand options for antibacterial therapies but have not been systematically tested in Gram-positive species. We profiled ~8,000 combinations of 65 antibacterial drugs against the model species Bacillus subtilis and two prominent ... ...

    Abstract Drug combinations can expand options for antibacterial therapies but have not been systematically tested in Gram-positive species. We profiled ~8,000 combinations of 65 antibacterial drugs against the model species Bacillus subtilis and two prominent pathogens, Staphylococcus aureus and Streptococcus pneumoniae. Thereby, we recapitulated previously known drug interactions, but also identified ten times more novel interactions in the pathogen S. aureus, including 150 synergies. We showed that two synergies were equally effective against multidrug-resistant S. aureus clinical isolates in vitro and in vivo. Interactions were largely species-specific and synergies were distinct from those of Gram-negative species, owing to cell surface and drug uptake differences. We also tested 2,728 combinations of 44 commonly prescribed non-antibiotic drugs with 62 drugs with antibacterial activity against S. aureus and identified numerous antagonisms that might compromise the efficacy of antimicrobial therapies. We identified even more synergies and showed that the anti-aggregant ticagrelor synergized with cationic antibiotics by modifying the surface charge of S. aureus. All data can be browsed in an interactive interface ( https://apps.embl.de/combact/ ).
    MeSH term(s) Staphylococcus aureus ; Methicillin-Resistant Staphylococcus aureus ; Anti-Bacterial Agents/pharmacology ; Gram-Positive Bacteria ; Drug Combinations
    Chemical Substances Anti-Bacterial Agents ; Drug Combinations
    Language English
    Publishing date 2023-09-28
    Publishing country England
    Document type Journal Article
    ISSN 2058-5276
    ISSN (online) 2058-5276
    DOI 10.1038/s41564-023-01486-9
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  6. Article ; Online: Drug-perturbation-based stratification of blood cancer.

    Dietrich, Sascha / Oleś, Małgorzata / Lu, Junyan / Sellner, Leopold / Anders, Simon / Velten, Britta / Wu, Bian / Hüllein, Jennifer / da Silva Liberio, Michelle / Walther, Tatjana / Wagner, Lena / Rabe, Sophie / Ghidelli-Disse, Sonja / Bantscheff, Marcus / Oleś, Andrzej K / Słabicki, Mikołaj / Mock, Andreas / Oakes, Christopher C / Wang, Shihui /
    Oppermann, Sina / Lukas, Marina / Kim, Vladislav / Sill, Martin / Benner, Axel / Jauch, Anna / Sutton, Lesley Ann / Young, Emma / Rosenquist, Richard / Liu, Xiyang / Jethwa, Alexander / Lee, Kwang Seok / Lewis, Joe / Putzker, Kerstin / Lutz, Christoph / Rossi, Davide / Mokhir, Andriy / Oellerich, Thomas / Zirlik, Katja / Herling, Marco / Nguyen-Khac, Florence / Plass, Christoph / Andersson, Emma / Mustjoki, Satu / von Kalle, Christof / Ho, Anthony D / Hensel, Manfred / Dürig, Jan / Ringshausen, Ingo / Zapatka, Marc / Huber, Wolfgang / Zenz, Thorsten

    The Journal of clinical investigation

    2017  Volume 128, Issue 1, Page(s) 427–445

    Abstract: As new generations of targeted therapies emerge and tumor genome sequencing discovers increasingly comprehensive mutation repertoires, the functional relationships of mutations to tumor phenotypes remain largely unknown. Here, we measured ex vivo ... ...

    Abstract As new generations of targeted therapies emerge and tumor genome sequencing discovers increasingly comprehensive mutation repertoires, the functional relationships of mutations to tumor phenotypes remain largely unknown. Here, we measured ex vivo sensitivity of 246 blood cancers to 63 drugs alongside genome, transcriptome, and DNA methylome analysis to understand determinants of drug response. We assembled a primary blood cancer cell encyclopedia data set that revealed disease-specific sensitivities for each cancer. Within chronic lymphocytic leukemia (CLL), responses to 62% of drugs were associated with 2 or more mutations, and linked the B cell receptor (BCR) pathway to trisomy 12, an important driver of CLL. Based on drug responses, the disease could be organized into phenotypic subgroups characterized by exploitable dependencies on BCR, mTOR, or MEK signaling and associated with mutations, gene expression, and DNA methylation. Fourteen percent of CLLs were driven by mTOR signaling in a non-BCR-dependent manner. Multivariate modeling revealed immunoglobulin heavy chain variable gene (IGHV) mutation status and trisomy 12 as the most important modulators of response to kinase inhibitors in CLL. Ex vivo drug responses were associated with outcome. This study overcomes the perception that most mutations do not influence drug response of cancer, and points to an updated approach to understanding tumor biology, with implications for biomarker discovery and cancer care.
    MeSH term(s) Antineoplastic Agents/therapeutic use ; Chromosomes, Human, Pair 12/genetics ; Chromosomes, Human, Pair 12/metabolism ; Databases, Factual ; Female ; Hematologic Neoplasms/classification ; Hematologic Neoplasms/drug therapy ; Hematologic Neoplasms/genetics ; Hematologic Neoplasms/pathology ; Humans ; Leukemia, Lymphocytic, Chronic, B-Cell/classification ; Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy ; Leukemia, Lymphocytic, Chronic, B-Cell/pathology ; Male ; Models, Biological ; Neoplasm Proteins/genetics ; Neoplasm Proteins/metabolism ; Signal Transduction ; Trisomy/genetics
    Chemical Substances Antineoplastic Agents ; Neoplasm Proteins
    Language English
    Publishing date 2017-12-11
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 3067-3
    ISSN 1558-8238 ; 0021-9738
    ISSN (online) 1558-8238
    ISSN 0021-9738
    DOI 10.1172/JCI93801
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ua VI Zs.184: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top